In last couple of years, multiple agents have been identified as potent inhibitors of DHODH that trigger some differentiation of AML cell lines [14–19], patient AML cells ex vivo [19] or patient-derived xenografts in vivo [18, 19], and four clinical trials are underway in order to establish their safety and efficiency in AML patients [20]. This evidence concerns the gene DHODH and acute myeloid leukemia.